Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEADE PanTumor: M9140 in Advanced Solid Tumors
NCT06710132Phase 2Active, not recruiting
- Sponsor
- EMD Serono
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of precemtabart tocentecan in gastric cancer (GC), non-small cell lung cancer (NSCLC), pancreatic cancer (PC), sponsored by EMD Serono. Started Jan 2025; status: active, not recruiting.
02
Drugs
precemtabart tocentecan
03
Conditions
gastric cancer (GC)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06710132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710132.